Employees: 1-10
Total raised: $30M
Founded date: 2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.10.2021 | Series C | $30M | - |
Mentions in press and media 7
| Date | Title | Description |
| 18.03.2025 | Chance Pharma's New Funding: A Breath of Fresh Air for Inhalation Therapies | In the world of biotechnology, funding is the lifeblood that fuels innovation. On March 17, 2025, Chance Pharmaceuticals, a clinical-stage company based in Hangzhou, China, secured a significant financial boost. This funding, though undiscl... |
| 17.03.2025 | Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies | HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the suc... |
| 17.03.2025 | Chance Pharma Raises New Funding | Chance Pharma, a Hangzhou, China-based clinical-stage biotechnology company, raised an undisclosed amount in new funding. Backers included Heda Health Fund and Qihang Venture Capital. The company intends to use the funds to support the adva... |
| 08.05.2023 | Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China | HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, H... |
| 12.10.2021 | Chance Pharmaceuticals Raises $30M in Series C Funding | Chance Pharmaceuticals, a Hangzhou, China-based clinical-stage biotechnology company, raised $30M in Series C financing. The round was led by Lapam Capital with participation from CMS Capital and HEDA BioVenture and existing investor Guozho... |
| 11.10.2021 | Chance Pharmaceuticals Secures $30 Million Series C Funding to Advance Innovative Pipeline and Initiate Additional Business Collaborations | HANGZHOU, China, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation therapies for the world’s debilitating diseases... |
| 10.10.2021 | Chance Pharmaceuticals Secures $30 Million Series C Funding to Advance Innovative Pipeline and Initiate Additional Business Collaborations | HANGZHOU, China, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing inhalation therapies for the world’s debilitating diseases... |